Ver ítem
- xmlui.general.dspace_homeCentros e Institutos de InvestigaciónCICVyA. Centro de Investigación en Ciencias Veterinarias y AgronómicasInstituto de BiotecnologíaArtículos científicosxmlui.ArtifactBrowser.ItemViewer.trail
- Inicio
- Centros e Institutos de Investigación
- CICVyA. Centro de Investigación en Ciencias Veterinarias y Agronómicas
- Instituto de Biotecnología
- Artículos científicos
- Ver ítem
SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
Resumen
Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the
[ver mas...]
Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in enhancing VSV-Δ51 viral production and oncolytic activity. To test this hypothesis, we first generated a novel VSV-Δ51 mutant that encoded the SARS-COV-2 RBD and compared viral spreading and viral yield between VSV-Δ51-RBD and VSV-Δ51 in vitro. Using the viral plaque assay, we demonstrated that the presence of the SARS-CoV-2 RBD in the VSV-Δ51 genome is associated with a significantly larger viral plaque surface area and significantly higher virus titers. Subsequently, using an ATP release-based assay, we demonstrated that the SARS-CoV-2 RBD could enhance VSV-Δ51 oncolytic activity in vitro. This observation was further supported using the B16F10 tumor model. These findings highlighted a novel use of the SARS-CoV-2 RBD as an anticancer agent.
[Cerrar]
Autor
Alkayyal, Almohanad A.;
Ajina, Reham;
Cacciabue, Marco Polo Domingo;
Alkayyal, Aaesha A.;
Saeedi, Nizar H.;
Hussain Alshehry, Taofik;
Kaboha, Feras;
Alotaibi, Mohammed A.;
Zaidan, Nada;
Shah, Khalid;
Alroqi, Fayhan;
Bakur Mahmoud, Ahmad;
Fuente
Frontiers in Immunology 14 : 1082191 (Enero 2023)
Fecha
2023-01
Editorial
Frontiers Media
ISSN
1664-3224
Formato
pdf
Tipo de documento
artículo
Palabras Claves
Derechos de acceso
Abierto
Excepto donde se diga explicitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)